APTIOM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aptiom, and when can generic versions of Aptiom launch?
Aptiom is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred patent family members in twenty-six countries.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aptiom
A generic version of APTIOM was approved as eslicarbazepine acetate by DR REDDYS on June 29th, 2021.
Summary for APTIOM
International Patents: | 100 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Clinical Trials: | 3 |
Patent Applications: | 282 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for APTIOM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APTIOM |
What excipients (inactive ingredients) are in APTIOM? | APTIOM excipients list |
DailyMed Link: | APTIOM at DailyMed |
Recent Clinical Trials for APTIOM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sunovion | Phase 3 |
Sunovion | Phase 4 |
Stanford University | Phase 4 |
Pharmacology for APTIOM
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Anatomical Therapeutic Chemical (ATC) Classes for APTIOM
Paragraph IV (Patent) Challenges for APTIOM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
APTIOM | Tablets | eslicarbazepine acetate | 200 mg, 400 mg, 600 mg and 800 mg | 022416 | 7 | 2017-11-08 |
US Patents and Regulatory Information for APTIOM
APTIOM is protected by fifteen US patents.
Patents protecting APTIOM
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Asymmetric catalytic reduction of oxcarbazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Asymmetric catalytic reduction of oxcarbazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Treatments involving eslicarbazepine acetate or eslicarbazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Treatments involving eslicarbazepine acetate or eslicarbazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
Therapeutical uses of eslicarbazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-004 | Nov 8, 2013 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for APTIOM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-004 | Nov 8, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-001 | Nov 8, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-002 | Nov 8, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for APTIOM
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
BIAL - Portela & Ca, S.A. | Zebinix | eslicarbazepine acetate | EMEA/H/C/000988 Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. |
Authorised | no | no | no | 2009-04-21 | |
BIAL - Portela Ca, S.A. | Exalief | eslicarbazepine acetate | EMEA/H/C/000987 Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. |
Withdrawn | no | no | no | 2009-04-21 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for APTIOM
When does loss-of-exclusivity occur for APTIOM?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5917
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 06273874
Estimated Expiration: ⤷ Try a Trial
Austria
Patent: 20665
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0615970
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 16984
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1277937
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 11988
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 15346
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 15346
Estimated Expiration: ⤷ Try a Trial
Patent: 19836
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 95765
Estimated Expiration: ⤷ Try a Trial
Patent: 09502893
Estimated Expiration: ⤷ Try a Trial
Patent: 13173764
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 08001291
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 5462
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 15346
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 3467
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 39060
Estimated Expiration: ⤷ Try a Trial
Patent: 08107718
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 15346
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 0800986
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1362281
Estimated Expiration: ⤷ Try a Trial
Patent: 080036212
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 71556
Estimated Expiration: ⤷ Try a Trial
Patent: 62816
Estimated Expiration: ⤷ Try a Trial
United Kingdom
Patent: 15690
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering APTIOM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2847235 | TRAITEMENTS METTANT EN JEU DE L'ACETATE D'ESLICARBAZEPINE OU DE L'ESLICARBAZEPINE (TREATMENTS INVOLVING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE) | ⤷ Try a Trial |
New Zealand | 578331 | THERAPEUTICAL USES OF ESLICARBAZEPINE | ⤷ Try a Trial |
Japan | 2017014233 | 酢酸リカルバゼピンを含む経口剤形 (ORAL DOSAGE FORM CONTAINING LICARBAZEPINE ACETATE) | ⤷ Try a Trial |
Poland | 324313 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for APTIOM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1915346 | C01915346/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020 |
0751129 | CA 2009 00023 | Denmark | ⤷ Try a Trial | |
0751129 | 09C0040 | France | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421 |
0751129 | SPC027/2009 | Ireland | ⤷ Try a Trial | SPC027/2009: 20091119, EXPIRES: 20210627 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |